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Liposomal drug delivery enhances the tumour selective localisation and may improve the uptake compared to free drug. However,
the drug distribution within the tumour tissue may still be heterogeneous. Degradation of the extracellular matrix is assumed to
improve the uptake and penetration of drugs. The effect of the ECM-degrading enzyme hyaluronidase on interstitial fluid pressure
and microvascular pressure were measured in human osteosarcoma xenografts by the wick-in-needle and micropipette technique,
respectively. The tumour uptake and distribution of liposomal doxorubicin were studied on tumour sections by confocal laser
scanning microscopy. The drugs were injected i.v. 1h after the hyaluronidase pretreatment. Intratumoral injection of hyaluronidase
reduced interstitial fluid pressure in a nonlinear dose-dependent manner. Maximum interstitial fluid pressure reduction of
approximately 50% was found after injection of 1500U hyaluronidase. Neither intratumoral nor i.v. injection of hyaluronidase induced
any changes in the microvascular pressure. Thus, hyaluronidase induced a transcapillary pressure gradient, resulting in a four-fold
increase in the tumour uptake and improving the distribution of the liposomal doxorubicin. Hyaluronidase reduces a major barrier for
drug delivery by inducing a transcapillary pressure gradient, and administration of hyaluronidase adjuvant with liposomal doxorubicin
may thus improve the therapeutic outcome.
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Liposomal doxorubicin may enhance the antitumour effect, and
reduce the toxicity by improved pharmacokinetics compared with
free doxorubicin. The polyethylene glycol (pegylated) coating
reduces cellular reticuloendothelial system uptake and prolongs
the circulation time (Gabizon et al, 1994). This, in combination
with the ability of liposomes to extravasate through leaky tumour
vessels (Wu et al, 1993; Yuan et al, 1994), contributes to selective
localisation of liposomal doxorubicin in tumour tissue (Gabizon
and Martin, 1997; Symon et al, 1999). In normal tissue, the intact
liposomes are confined to the intravascular space, as normal blood
vessels are not fenestrated to the same degree as in tumour tissue.
Hence, the toxicity to normal tissue is reduced considerably,
especially cardiotoxicity (Harris et al, 2002). Although liposomal
delivery of doxorubicin improves the tumour uptake compared to
free doxorubicin, the drug distribution within the tumour tissue is
still heterogeneous (Vaage et al, 1997; Davies et al, 2004).
The enzyme hyaluronidase degrading hyaluronan is reported, in
phase I and II trials, to prevent regrowth of various tumour types
and to improve clinical outcome when given adjuvant to
chemotherapy (Baumgartner, 1987; Maier and Baumgartner,
1989; Smith et al, 1997), and delays the growth of human breast
cancer xenografts compared with doxorubicin given alone, when
given as a pretreatment to doxorubicin (Beckenlehner et al, 1992).
However, it has been reported that such pretreatment may induce
drug resistance (Chang, 2001). Experiences from various clinical
trials show that hyaluronidase seemingly has no toxicity towards
normal tissues or and other adverse effects when used in various
clinical trials (Bruera et al, 1999; Menon et al, 1999; Albanell and
Baselga, 2000). This is also shown in preclinical experiments
(Shuster et al, 2002). The mechanism for the enhanced therapeutic
effect is not well known, but degradation of the ECM is assumed to
improve the penetration of the drug. Delivery of drug to tumour
cells occurs by two independent mechanisms: diffusion due to the
concentration gradient and convection due to pressure gradients.
In avascular multicellular spheroids, diffusion is the only
mechanism of transportation, and the observed improved
penetration of doxorubicin into spheroids incubated with hyalur-
onidase is thus probably due to this mechanism (Kohno et al,
1994). The high interstitial fluid pressure (IFP), which is driven by
the microvascular pressure (MVP), is a major obstacle to
penetration of therapeutic molecules, as the transcapillary pressure
gradient is low, and an outward interstitial flux is generated toward
the periphery of the tumour due to the steep pressure gradient in
the periphery of the tumour (Boucher and Jain, 1992; Eikenes et al,
2004). We have previously shown that hyaluronidase reduced IFP
(Brekken et al, 2000a) and periodic changes in IFP by
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shyaluronidase increased the tumour uptake of radiolabelled moab
in human osteosarcoma xenografts (Brekken et al, 2000b).
Based on the above, we postulated that hyaluronidase might
induce a transcapillary pressure gradient, thereby improving
the tumour uptake and distribution of liposomal doxorubicin
within the tumour. To test this hypothesis, IFP and MVP were
measured by the wick-in-needle and micropipette technique,
respectively, after intratumoral or intravenous injection of
hyaluronidase in athymic mice bearing human osteosarcoma
xenografts. The tumour uptake and distribution of liposomal
doxorubicin injected i.v. 1h after the hyaluronidase injection
was studied on tumour sections by confocal laser scanning
microscopy (CLSM).
MATERIAL AND METHODS
Animal and tumour models
Xenografts were grown in 7–9-week-old athymic female BALB/c
nu/nu mice (Taconic, M&M, Denmark) either orthotopically (o.t.)
or subcutaneously (s.c.), by injecting 100ml suspension of 2 10
6
human osteosarcoma cells from the cell line OHS (Fodstad et al,
1986) either adjacent to the periosteum of the femurs or
subcutaneously. The orthotopic tumours were growing around
and infiltrating the bones. Growth kinetics and histology of the two
tumour models have been reported previously (Brekken et al,
2000a). The xenografts were grown for 3–6 weeks, and the tumour
sizes ranged from 0.7 to 1.7cm
3. The animals were kept under
pathogen-free conditions and were allowed food and water ad
libitum. All animal experiments have been carried out with ethical
committee approval. The ethical guidelines that were followed
meet the standards required by the UKCCCR guidelines.
Treatments
The mice were anaesthetised with an s.c. injection of Hypnorm/
Dormicum/sterile water,1:1:2, 4mlkg
 1 bodyweight (Janssen
Pharmaceutical, Belgium, and Alpharma AS, Norway) during all
surgical and experimental procedures. Hyaluronidase (Neoper-
mease
s, Sandoz-Novartis, kindly provided by Professor G
Baumgartner) was injected intratumorally in various concentra-
tions diluted in PBS to a final volume of 50ml, or 50ml (1500U in
50ml) was administrated into the tail vein. Liposomal doxorubicin
(Caelyx
TM, Schering Plough, Norway) was injected into the tail
vein 1h after hyaluronidase administration, using 16mgkg
 1 in
200ml PBS.
Interstitial fluid pressure
Interstitial fluid pressure was measured in orthotopic and
subcutaneous tumours using the wick-in-needle technique (Fadnes
et al, 1977). In brief, a hypodermic needle (size G23) was placed
centrally in the tumour and connected to a pressure transducer
(SensoNor 840, Norway) via polyethylene tubing (PI-50, Becton-
Dickinson, MD, USA) filled with sterile heparinised PBS
(70Uml
 1). Pressures were monitored online using a MacLab
analogue to digital recording system with a sampling rate of 4Hz
(MacLab4/e, ADInstruments, UK). Fluid communication between
the needle and the tumour tissue was tested by compression and
decompression of the polyethylene tubing and accepted when the
IFP did not differ more than 20%.
Prior to needle insertion, the pressure was set to zero at the
equator of the tumour. The needle was carefully inserted into the
centre of the tumour mass, allowing the IFP to equilibrate for 10–
15min. After reaching a stable IFP value, hyaluronidase was
injected. Interstitial fluid pressure was recorded continuously up
to 100min after the injection. Control tumours received PBS.
Microvascular pressure measurements
Microvascular pressure was measured in subcutaneous tumours
using micropipettes and a servo-controlled counter-pressure
system (Wiederhielm et al, 1964). The counter-pressure was
generated to balance the change in the electrical resistance in the
micropipette. The generated counter-pressure represents the
actual MVP and was amplified and recorded using the same
MacLab analogue to digital recording system as for the WIN
technique. A micromanipulator (Narishige MMN-333, Japan) and
a stereomicroscope (Nikon SMZ-10A, Japan) were used to place
the pipette into visible, peripheral vessels. The micropipettes were
made from borosilicat glass capillaries (GC100-15, 1.0mm
o.d. 0.58mm i.d., Harvard Apparatus, UK) using a horizontal
pipette puller (PN-3, Narishige, Japan). A microbeveller (TMB 100
Turbo Microbeveller, WPI, UK) grounded the tip of the micro-
pipettes, making a tip diameter of about 5mm.
The skin overlying the tumour was removed before
micropuncture, and zero pressure was recorded in the saline
film covering the wound. Microvascular pressure was measured
in one vessel per tumour. After the first MVP measurement,
50ml hyaluronidase (1500U) was injected intratumorally or i.v.
The micropipette was withdrawn during the injection to avoid
breakage of the pipette. Control tumours received 50ml PBS alone,
given intratumourally or i.v. Microvascular pressure was measured
up to 100min after the hyaluronidase injection, but was not
measured continuously throughout the experiment due to
replacement of the pipette because of frequent pipette breakage
and clogging.
The MVP was only measured in s.c. tumours because at this
tumour site it was possible to observe the microvessels after
removing the overlying skin. The IFP was also measured in o.t.
tumours as this is physiologically a more correct mode.
Preparation of tumour sections and immunofluorescence
staining
Mice were killed by cervical dislocation 2 days after injection
of liposomal doxorubicin, the tumours were excised, embedded
in tissue Tec (O.C.T.t Coumpound, Sakura, Netherlands), frozen
in liquid N2 and 5mm thick tumour sections were mounted
on glass slides.
When staining blood vessels, the tumour sections were fixed in
acetone for 10min and incubated in goat serum to prevent
nonspecific binding. The vessels were stained using rat anti-mouse
CD31 antibody (clone MEC13.3; PharMingen, CA, USA)
(16.7mgml
 1) for 1h, followed by either biotinylated goat anti-
rat IgG (Vector Lab, CA, USA) (10mgml
 1) and streptavidin Alexa
Fluor 633 (Molecular Probes, OR, USA) (100mgml
 1), when
colocalised with doxorubicin, or by rabbit anti-rat IgG (diluted
1:200) (DakoCytomation, Glostrup, Denmark), goat anti-rabbit
Dako Envision (100ml) (DakoCytomation, Glostrup, Denmark)
and rabbit anti-goat IgG Alexa Fluor 488 (10mgml
 1) (Molecular
Probes, Eugene, OR, USA), when colocalised with hyaluronan.
When staining hyaluronan, the tumour sections were incubated
with PBS containing 3% bovine serum albumin for 1h to prevent
nonspecific binding. Hyaluronan was labelled by incubating the
sections for 1h with biotinylated hyaluronan-binding protein (b-
HABP, Seikagaku America, MA, USA) (10mgml
 1), followed by
incubation with stuptavidin Alexa Fluor 633 (Molecular Probes,
OR, USA)(10mgml
 1) for 30min.
When staining DNA, the tumour sections were equilibrated
briefly in PBS and incubated with Hoechst 33258 (Molecular
Probes, OR, USA) (1mgml
 1) for 5min and rinsed in PBS for
1min.
All incubations were carried out at room temperature in a
humid chamber, and the sections were rinsed with PBS after each
incubation.
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Released doxorubicin, blood vessels, hyaluronan and DNA were
localised on frozen tumour sections using a confocal laser
scanning microscope objective (LSM510, Zeiss, Germany). Colo-
calisation of doxorubicin and blood vessels was examined using an
X20/0.3 objective. The colocalisation of doxorubicin and DNA was
studied using an X63/1.2 water objective. The colocalisation of
hyaluronan, DNA and blood vessels was studied using an X40/1.2
water objective. A 488nm argon laser line was used to excite
doxorubicin and rabbit anti-goat-IgG-Alexa488, a 633nm HeNe
laser line was used to excite streptavidin Alexa Fluor 633 and a
two-photon mode locked Ti:sapphire laser (Mira Model 900 – F,
Coherent, Inc., Laser Group, Santa Clara, CA, USA) at l¼780nm
was used to excite Hoechst 33258.
Doxorubicin encapsulated in liposomes had a concentration that
quenched the fluorescence. Doxorubicin does not bind covalently
to the cells and was therefore washed away during the vessel
labelling procedure. Colocalisation of doxorubicin and blood
vessels had, therefore, to be assessed by sequentially imaging. The
doxorubicin distribution was recorded before labelling the vessels,
followed by imaging the same section and position with stained
vessels. The sections were imaged along a radial track from the
periphery to the centre. The start position of the track was marked,
and based on this mark as well as the vessel structures the two
images were easily overlayed. All images had a resolution of
512 512 pixels. Laser current and detector gain were chosen to
minimise noise and to utilise all grey values.
The uptake of doxorubicin was quantified by measuring the
average fluorescence intensity per image. The fluorescence intensity
was measured along a horizontal and vertical radial track from the
periphery through the centre to the other periphery. In all, 6–16
images were recorded per section depending on the position of the
section within the tumour and the size of the tumour. This was
carried out for 10 sections per tumour and three tumours per group
of treatment. Each section was 150–200mma p a r t ,a n dt h ef i r s t
section was approximately 2mm from the tumour periphery.
Quantitative measurements require that the fluorescence is not
attenuated nor bleached. As the sections were only 5mmt h i c k ,
attenuation will negligible. Bleaching of doxorubicin fluorescence
was measured by scanning sections continuously for 2min. No
change in the fluorescence intensity was observed, demonstrating
the absence of bleaching with the settings used.
Statistical analysis
Curve fitting of theoretical models to experimental data was
performed using Sigma Plot (SPSS Inc. Headquarters, IL, USA).
The changes in pressures, relative to pretreatment values, were
determined individually for each tumour, and then averaged.
Gaussian pressure data were analysed using Student’s t tests
(Minitab, Minitab Inc., State College, PA, USA).
Statistical analysis of doxorubicin fluorescence intensity data at
each time point was performed using one-way analysis of variance,
ANOVA. The frequency of images as a function of fluorescence
intensity was analysed using the 5 2 contingency table and Chi-
squared test. The contigency table contained a number of images
with intensity values of 0–5 for the two groups, Caelyxt alone or
combined with hyaluronidase. All statistical analysis was per-
formed using the significance criterion of P¼0.05.
RESULTS
Effect of hyaluronidase on IFP
Intratumoral injection of hyaluronidase in o.t. tumours reduced
IFP in a dose-dependent manner up to a maximum reduction of
approximately 40% after 1500U of hyaluronidase (n¼6) (Figures
1, 2). However, by increasing the dose further to 3000U (n¼6),
IFP was reduced to a lesser extent; approximately 20% (Figure 1).
A further increase to 5000U was lethal. Statistical analysis showed
that for all doses of hyaluronidase except 150U (n¼6) (P¼0.052),
the maximum reduction in IFP was significantly lower than the
constant IFP level measured in control tumours injected with PBS
(Po0.05). In addition, the reduction induced by 1500U of
hyaluronidase was significantly greater than the reduction induced
by the other doses (Po0.05).
Maximum reduction in IFP was obtained approximately 1h after
hyaluronidase injection. The time response of the IFP reduction
after intratumoral injection of hyaluronidase was biexponential
with a fast (tv) and a slow (ti) time constant (Figure 2). The time
response was normalised to the pressure before the hyaluronidase
injection. An initial increase in IFP was observed, probably due to
an increase in the volume and compression of the tissue at the
moment of the intratumoral injection. Fitting the experimental
data to the theoretical biexponential function
IFP ¼ Ae tv þ Be ti þ IFP1
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Figure 1 Maximum reduction (%) in IFP 1h after intratumoral injection
of PBS (n¼5), 150U (n¼6), 500U (n¼5), 1500U (n¼6) and 3000U
(n¼6) hyaluronidase in o.t. tumours. Each value is the mean of n tumours,
the bars represent s.e. *Data significantly different from untreated controls.
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Figure 2 Interstitial fluid pressure response as a function of time after
intratumoral injection of 150U () (n¼4), 500U (D)( n¼5), 1500U
(r)(n¼4) and 3000U (&)( n¼6) hyaluronidase in o.t. tumours.
Interstitial fluid pressure is normalised to IFP before the injection. Each
curve is the mean of n measurements.
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constants were approximately tvE50s and tiE10000s, respec-
tively, for the doses up to 1500U. Hyaluronidase (3000U) induced
a slower reduction with time constants of approximately tvE300s
and tiE20000s.
The maximum reduction in IFP correlated inversely with the
tumour volume (Figure 3), except for the lowest dose used (150U).
Statistical analysis showed a significant correlation for 500U
(R
2¼0.79, P¼0.044) and for 1500U (R
2¼0.97, P¼0.00), and
almost significant for 3000U (R
2¼0.64, P¼0.055). Interstitial fluid
pressure was thus reduced to a greater extent in the smaller tumours.
Intravenous administration of 1500U hyaluronidase in s.c.
(n¼2) tumours induced approximately the same maximum
reduction in IFP as the intratumoral injection of 1500U
hyaluronidase (Figure 4B). However, the time response was longer,
and the maximum reduction stabilised 100min after the hyalur-
onidase injection.
Effect of hyaluronidase on MVP
Intratumoral (n¼5) as well as i.v. (n¼7) injection of neither 1500U
hyaluronidase nor PBS (data not shown) had any significant effect on
MVP in s.c. tumours (Figure 4). Previous studies have shown that
intratumoral injection of hyaluronidase does not affect mean arterial
blood pressure either (Brekken et al, 2000a).
Effect of hyaluronidase on hyaluronan in the tumour tissue
Immunofluorescence staining showed that hyaluronan surrounded
most of the vasculature in the untreated tumours. In addition,
polymers of hyaluronan were located heterogeneously throughout
the tumour (Figure 5A). Intense hyaluronan staining was seen at the
rim of the tumours. Hyaluronidase had a diverse effect on the
structure of hyaluronan, disintegrating both vascular associated and
interstitial hyaluronan in some areas (Figure 5B), and leaving
hyaluronan intact in other areas (Figure 5C). However, quanititative
measurements of the hyaluronan fluorescence intensity showed no
change after the hyaluronidase treatment (data not shown).
Distribution of doxorubicin
The distribution of doxorubicin in the periphery and central parts of
the tumour was compared by imaging tumour sections along a radial
track from the periphery to the centre of the section. In untreated
tumours, liposomal doxorubicin was mainly located in the periphery
of the tumour. The drug was found up to 450mmf r o mt h er i mo ft h e
tumour. In tumours only treated with liposomal doxorubicin, hardly
any doxorubicin fluorescence was detected in the central part of the
tumours (Figure 6A). Hyaluronidase improved the distribution of
doxorubicin considerably, although doxorubicin was still rather
heterogeneously distributed. Hyaluronidase allocated doxorubicin
further away from the vessels in the periphery, and doxorubicin was
located around vessels in the central part of the section where no
doxorubicin was observed in tumours given liposomal doxorubicin
alone (Figure 6B).
Quantitative measurements of doxorubicin uptake
To obtain more quantitative data of doxorubicin distribution and
uptake, the doxorubicin fluorescence intensity was quantified by
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Figure 3 Maximum reduction in IFP after intratumoral injection of hyaluronidase as a function of tumour volume. Each symbol represents one
measurement, the solid line represents linear regression analysis and was found to be significant for all doses except 150U.
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sestimating the average pixel intensity per image (Figure 7), and by
estimating the fluorescence pixel area per image (data not shown).
Both measurements gave similar results. The measurements were
made along two perpendicular radial tracks on 10 sections per
tumour in three tumours. The uptake of doxorubicin in the
periphery was six to nine times higher than that in the other parts
of the tumours when liposomal doxorubicin was given alone, and
two to six times higher in the periphery of tumours treated with
hyaluronidase (Figure 7). Hyaluronidase increased the uptake of
doxorubicin two to eight times throughout the whole tumour, and
in the central parts of the tumour hyaluronidase increased the
uptake of doxorubicin approximately four times (Figure 7). An
ANOVA comparing tumours treated with hyaluronidase and
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Figure 4 Normalised pressure after (A) intratumoral and (B) i.v.
injection of 1500U hyaluronidase in s.c. tumours. Microvascular pressure
(K) was not measured continuously, and the data are based on different
time intervals for n¼5 (intratumoral injection) and n¼7 (i.v. injection)
mice. The bars represent s.e. at some time points. The IFP (J) graph is the
mean of n¼2 measurements.
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Figure 6 Distribution of liposomal doxorubicin in osteosarcoma xenografts treated with liposomal doxorubicin alone (16mgkg
 1)( A) or liposomal
doxorubicin combined with hyaluronidase (1500U) (B). Representative images of doxorubicin (green) relative to capillaries (red) are presented from the
rim to the centre of the tumour sections.
B A
C
Figure 5 Tumour tissue hyaluronan (blue) in o.t. osteosarcoma
xenografts relative to capillaries (red) and tumour cells (green) treated
with PBS (A) and hyaluronidase (1500U) (B, C).
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stumours given liposomal doxorubicin alone showed that the
increase was significant throughout the whole tumour (Po0.05).
The improved distribution of doxorubicin induced by hyalur-
onidase was demonstrated also by plotting the number of images
as a function of fluorescence intensity. Tumours treated with
liposomal doxorubicin and hyaluronidase had a higher number of
images with detectable fluorescence than tumours treated with
liposomal doxorubicin alone (Figure 8). A Chi-squared test showed
that the number of images with no fluorescence was significantly
higher for tumours that are only treated with Caelyx
TM. This shows
that hyaluronidase redistributed doxorubicin to more areas of the
tumours.
Intracellular location of doxorubicin
Doxorubicin was located intracellularly, and hardly any fluores-
cence was seen in the ECM. The intracellular distribution of
doxorubicin was mainly located in the nuclei, shown by
colocalisation of doxorubicin and DNA (Figure 9). Hyaluronidase
did not change the intracellular distribution.
DISCUSSION
Doxorubicin is one of the most effective drugs in the management
of osteosarcoma (Bruland and Pihl, 1997; Ferguson and Goorin,
2001). Although liposomal delivery of doxorubicin improves the
tumour uptake compared to free doxorubicin, the drug distribu-
tion within the tumour tissue is still heterogeneous (Vaage et al,
1997; Davies et al, 2004). The present work showed that
hyaluronidase increased the transcapillary pressure gradient in
OHS xenografts, thereby improving the uptake and distribution of
liposomal doxorubicin.
Hyaluronidase reduced IFP in a nonlinear dose-dependent
manner, and the time-response of the IFP reduction followed a
biexponential function. We have previously suggested that the fast
initial time constant (tv) reflects increased transcapillary transport,
whereas the slower time constant (ti) reflects interstitial transport
(Brekken et al, 2000a; Eikenes et al, 2004). The present work
demonstrated that the hyaluronidase-induced reduction in IFP was
not caused by a reduction in MVP. Microvascular pressure
remained constant and thus an increased transcapillary pressure
gradient was established. Microvascular pressure is reported to
govern IFP (Boucher and Jain, 1992) due to the lack of a lymphatic
network and high vascular permeability. However, hyaluronidase
reduced IFP independently of MVP, probably by the interstitial
degradation of ECM. Hyaluronidase degrades extracellular hyalur-
onan by cleaving b-N-acetyl-hexoamine glycocidic bonds, which
changes the overall structure of the ECM. Interstitial fluid pressure
is reported to correlate inversely with the interstitial hydraulic
conductivity (Jain and Baxter, 1988; Boucher et al, 1990), which
correlates inversely with the concentration of glycosaminoglycans
(Swabb et al, 1974). A reduction in glycosaminoglycans by
hyaluronidase may thus increase the hydraulic conductivity,
thereby reducing IFP. On the other hand, hyaluronidase induced
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Figure 7 Doxorubicin fluorescence intensity profile in osteosarcoma
xenografts treated with liposomal doxorubicin alone (16mgkg
 1)( J)o r
combined with hyaluronidase (1500U) (K). Each symbol is the mean of
5–20 images per section and 10 sections per tumour in three tumours.
Bars represent s.e. The increase in the doxorubicin uptake in the
hyaluronidase-treated tumours is significant throughout the whole tumour
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Figure 9 Intracellular distribution of doxorubicin (green) (A), DNA
(red) (B) and colocalisation of doxorubicin and DNA (C) in osteosarcoma
xenografts given liposomal doxorubicin alone (16mgkg
 1). Bar¼20mm.
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sa nonlinear reduction in IFP, and the interstitial degradation using
the highest dose of hyaluronidase reduced IFP to a less extent.
Higher doses of hyaluronidase may collapse the water swelling
structure of hyaluronan to a greater extent, and induce cross-
binding of the ECM fragments, making the ECM more viscous and
less permeable. Such a nonlinear response has also been
demonstrated when measuring the ability to penetrate the
epithelial luminal glycocalyx after hyaluronidase treatment (Henry
and Duling, 1999).
The reduction in IFP correlated inversely with tumour volume.
This may be explained by a more efficient degradation of ECM due
to the more homogeneous distribution of hyaluronidase in smaller
tumours.
The route of administration of hyaluronidase had no impact on
the observed pressure responses, neither IFP nor MVP. This is
probably due to rapid vascular absorption of intratumoral-injected
hyaluronidase, which has been demonstrated by a reduction in IFP
in a secondary tumour only 40s after an injection in the primary
tumour (Brekken et al, 2000a).
Collagenase is another enzyme degrading the ECM. We have
previously shown that i.v. administration of collagenase reduced
IFP to the same extent and with the same kinetics as reported here
for hyaluronidase (Eikenes et al, 2004). The IFP reduction was
temporary and the recovery was similar for the two enzymes
(Brekken et al, 2000a; Eikenes et al, 2004). Hyaluronidase did not
induce any significant changes in MVP. Collagenase, however,
reduced MVP, probably by reducing the vascular resistance as
microvascular-associated collagen was disintegrated (Eikenes et al,
2004). Hyaluronan also surrounds vascular endothelial cells as an
integrated part of the plasma membrane glycoproteins and
glycolipids constituting the glycocalyx. The glycocalyx has been
shown to reduce the vascular permeability (Qiao et al, 1995; Henry
and Duling, 1999; Huxley and Williams, 2000; van Haaren et al,
2003) and contributes significantly to the hydraulic resistance of
the capillary wall (Adamson, 1990). The glycocalyx also restricts
the access of blood-borne macromolecules and cells to the luminal
surface of the endothelial cells, thus reducing the functional
diameter of the microvessels (Henry and Duling, 1999). Hyalur-
onidase has been found to increase the functional diameter for 70–
145kDa dextrans, but not for larger dextrans and red blood cells.
However, the anatomic diameter was not changed (Henry and
Duling, 1999); thus, hyaluronidase has probably no effect on the
vascular resistance. Consistent with this, immunofluorescence
staining of hyaluronan demonstrated that hyaluronidase induced a
heterogeneous degradation of hyaluronan, and vascular-associated
hyaluronan was only disintegrated around some vessels. Further-
more, quantitative measurements of the hyaluronan fluorescence
intensity showed no change in the intensity of the hyaluronidase-
treated sections, indicating that disintegrated hyaluronan is not
removed and/or the treatment may increase the number of binding
sites for the hyaluronan-binding protein as also found in a
previous study (Brekken et al, 2000a). Other glycoproteins and
proteoglycans as well as collagen also stabilise the vessel wall and
contribute to the vascular resistance. Thus, the stability of the MVP
after hyaluronidase treatment is probably due to the maintenance
of the vascular resistance.
The distribution of liposomal doxorubicin in untreated tumours
was heterogeneous, and mainly located in the periphery of the
tumours. This correlates spatially with the peripheral IFP gradient
previously measured in subcutaneous OHS xenografts (Eikenes
et al, 2004), where the high central IFP decreased rapidly in the
periphery of the tumour (0–400mm from the rim). In addition to
high IFP, the poor distribution may be due to heterogeneous
vascularisation and perfusion, slow interstitial diffusion and
efficient extravascular binding of doxorubicin mainly in the
tumour and endothelial cells.
Hyaluronidase increased the tumour uptake and improved the
distribution of liposomal doxorubicin. Doxorubicin was located
mainly around blood vessels in the periphery as well as in the
central parts of the tumour, where hardly any doxorubicin was
seen in untreated tumours. This suggests that the enhanced
transcapillary pressure gradient increased the transcapillary
transport of liposomes. Liposomes able to extravasate were
probably degraded efficiently (Martin, 1997) as few intact
liposomes were seen, and the released doxorubicin penetrated
somewhat further into the ECM. Intact Caelyx
TM liposomes have
previously been observed to remain within the vasculature or are
interstitial in very close proximity to the blood vessels (Davies
et al, 2004), indicating that these large molecules are not able to
penetrate away from the blood vessels and reach further into the
interstitium.
Hyaluronidase may also increase the interstitial diffusion
coefficient of doxorubicin. In avascular multicellular spheroids
where diffusion is the only transport mechanism, hyaluronidase
has been found to increase the penetration of doxorubicin (Kohno
et al, 1994). On the other hand, in tumours growing in dorsal
window chambers, both a fast and slow diffusive fraction of
macromolecules were demonstrated, and i.v. injection of hyalur-
onidase increased the proportion of the slowly diffusing IgG and
reduced the low diffusion coefficient, whereas no effect was seen
for the fast diffusing IgG (Alexandrakis et al, 2004). A positive
correlation between the diffusion coefficient of IgG and the
amount of hyaluronan has also been reported (Davies et al, 2002).
All together, this may reflect that the structure of the ECM is more
important for the penetration of macromolecules than the amount
of hyaluronan and other ECM constituents (Pluen et al, 2001;
Brown et al, 2003).
Hyaluronidase seems to be more efficient than radiation in
improving the distribution and uptake of Caelyxt in osteosarcoma
xenografts. We have previously reported that radiation (8Gy)
increased the uptake of Caelyxt in the central part of the tumour
two to four times (Davies et al, 2004). This suggests that the direct
degradation of ECM is more efficient in improving the transport of
macromolecules than in inactivating and inducing apoptosis in the
tumour cells and thereby modulating the ECM.
The present work demonstrates that hyaluronidase reduces the
barrier for drug delivery by inducing a transcapillary pressure
gradient. An efficient transcapillary pressure gradient is especially
important for the extravasation of large molecules such as
liposomes. Pre- or coadministration of hyaluronidase adjuvant with
liposomal doxorubicin may thus improve the therapeutic outcome.
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